Report initial data from the RP2 Phase 1 clinical trial cohort

Delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 30 Mar 2022
Due: 31 Dec 2022
Delivered: December 2022

Deadline
Met
Late
Not met
Today

What the company said

“initial data is expected later in the year”

SourceReplimune Group, Inc. Form 8-K press release, 2022-03-30
FilingSEC filing index
Deadline as statedlater in the year
Deadline used31 Dec 2022, the last day of the stated period
TypeProject
Permanent referenceKI-C-2022-REPL-002671
Cite as https://keptindex.org/c/KI-C-2022-REPL-002671/ — this address never changes.

What we found

Evidence strength A What the grades mean

The company reported initial data from the RP2 Phase 1 clinical trial cohort in December 2022, fulfilling the commitment to provide this data by the end of the year.

A
Replimune Group, Inc. 10-Q filed 2023-02-09 Regulatory filing · published 9 Feb 2023 · retrieved 1 Oct 2026 · kept permanently by the SEC
“In December 2022, we reported that of 14 patients with uveal melanoma for which sufficient follow-up was available for assessment, 4 patients had achieved a response.” ✓ confirmed on the page

Market reaction: the shares moved -11.9% against the S&P 500 over the three sessions around the disclosure (8 Feb 2023 to 13 Feb 2023). What this measures

Checked 1 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Deadline drift +1461 days
3 versions

Version 1 · original · stated 30 Mar 2022

Deadline 31 Dec 2022 (“later in the year”) · wording expected
Version 2 · stated 7 Aug 2025

Deadline 30 Jun 2026 (“the first half of 2026”) · wording expected

“The Phase 2 clinical trial of RP2 combined with atezolizumab and bevacizumab in anti-PD1/PD-L1 progressed HCC is currently enrolling with data anticipated in the first half of 2026.”
Source for this version
Version 3 · stated 6 Nov 2025

Deadline 31 Dec 2026 (“by the end of 2026”) · wording expected

“The protocol is being amended to include RP2 as monotherapy with data planned by the end of 2026.”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout
Indicative materiality: Medium rules
Action: Report
Deliverable: initial data for RP2 Phase 1 cohort
Language: Expected (“expects”, “plans”)
In the company’s control: Medium
Specificity: Medium
Depends on: Regulatory

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Replimune Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.